Isomorphic Labs
Isomorphic Labs is a drug discovery company that uses AI to predict how molecules behave and design new medicines, aiming to make the process faster and cheaper than traditional lab research.
Analytics date: 11.08.2026
Basic information
Head office
280 Bishopsgate, London, United Kingdom, EC2M 4AGHead officeDate of the last round
Last round 05/2026Date of the last roundTotal funds raised
$2.7B+Total funds raised
Analytics date: 11.08.2026
IPO Forecast
As of the current research date, Isomorphic Labs has no announced plans for an initial public offering. The company remains a private, autonomous subsidiary of Alphabet, which holds a majority stake following its two external funding rounds. Neither the company nor its leadership has disclosed an IPO timeline, target valuation, ticker, or exchange listing. On the contrary, the scale of its recent private financing — $600 million in March 2025 and $2.1 billion in its May 2026 Series B — suggests the company is well-capitalised to continue operating privately for the foreseeable future, with its stated near-term focus being to advance its first drug candidates toward clinical trials rather than to pursue a public listing.
Request price information
Competitor Analysis
Comparison with other companies in the industry.
| Name | Valuation |
| Private companies | |
Neuralink | 00000 |
Merge Labs | 0000 |
Precision Neuroscience | 0000 |
Capsule | 00 |
| Traded companies | |
NeuroMetrix | 0000 |
NeuroPace | 000 |
Recursion Pharmaceuticals | 0000 |
Schrödinger | 0000 |
Relay Therapeutics | 000 |
| Acquired companies | |
Alto Pharmacy | 0000 |